<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">nnp</journal-id><journal-title-group><journal-title xml:lang="en">Neurology, Neuropsychiatry, Psychosomatics</journal-title><trans-title-group xml:lang="ru"><trans-title>Неврология, нейропсихиатрия, психосоматика</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-2711</issn><issn pub-type="epub">2310-1342</issn><publisher><publisher-name>"IMA-Press", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/2074-2711-2024-2S-65-73</article-id><article-id custom-type="elpub" pub-id-type="custom">nnp-2318</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEW</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОР</subject></subj-group></article-categories><title-group><article-title>Neuromyelitis optica spectrum disorders in children</article-title><trans-title-group xml:lang="ru"><trans-title>Заболевания спектра оптиконевромиелита у детей</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1409-6704</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ахметгалеева</surname><given-names>Н. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Akhmetgaleeva</surname><given-names>N. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Наиля Фанильевна Ахметгалеева</p><p>450106, Уфа, ул. Степана Кувыкина, 98 Уфа; 450008, Уфа, ул. Ленина, 3</p></bio><bio xml:lang="en"><p>Nailya Fanilievna Akhmetgaleeva</p><p>98, Stepana Kuvykina St., Ufa 450106, Ufa; 3, Lenina St., Ufa 450008</p></bio><email xlink:type="simple">nailya_9292@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7256-2668</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Симанив</surname><given-names>Т. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Simaniv</surname><given-names>T. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>125367, Москва, Волоколамское шоссе, 80</p></bio><bio xml:lang="en"><p>80, Volokolamskoe Shosse, Moscow 125367</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3083-7413</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Яушева</surname><given-names>Э. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Yausheva</surname><given-names>E. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>450106, Уфа, ул. Степана Кувыкина, 98 Уфа</p></bio><bio xml:lang="en"><p>98, Stepana Kuvykina St., Ufa 450106, Ufa</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-3685-9501</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Саитова</surname><given-names>Я. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Saitova</surname><given-names>Yа. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>450008, Уфа, ул. Ленина, 3</p></bio><bio xml:lang="en"><p>3, Lenina St., Ufa 450008</p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1393-1122</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лютов</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Lyutov</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>450008, Уфа, ул. Ленина, 3</p></bio><bio xml:lang="en"><p>3, Lenina St., Ufa 450008</p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1001-2024</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кутлубаев</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kutlubaev</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>450008, Уфа, ул. Ленина, 3</p></bio><bio xml:lang="en"><p>3, Lenina St., Ufa 450008</p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0982-4324</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бахтиярова</surname><given-names>К. З.</given-names></name><name name-style="western" xml:lang="en"><surname>Bakhtiyarova</surname><given-names>K. Z.</given-names></name></name-alternatives><bio xml:lang="ru"><p>450008, Уфа, ул. Ленина, 3</p></bio><bio xml:lang="en"><p>3, Lenina St., Ufa 450008</p></bio><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГБУЗ «Республиканская детская клиническая больница»; ФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Republican Children's Clinical Hospital; Bashkir State Medical University, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБНУ «Научный центр неврологии»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Center of Neurology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ГБУЗ «Республиканская детская клиническая больница»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Republican Children's Clinical Hospital</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Bashkir State Medical University, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>07</day><month>08</month><year>2024</year></pub-date><volume>16</volume><issue>0</issue><issue-title>(Suppl. 2)</issue-title><fpage>65</fpage><lpage>73</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Akhmetgaleeva N.F., Simaniv T.O., Yausheva E.M., Saitova Y.A., Lyutov O.V., Kutlubaev M.A., Bakhtiyarova K.Z., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Ахметгалеева Н.Ф., Симанив Т.О., Яушева Э.М., Саитова Я.А., Лютов О.В., Кутлубаев М.А., Бахтиярова К.З.</copyright-holder><copyright-holder xml:lang="en">Akhmetgaleeva N.F., Simaniv T.O., Yausheva E.M., Saitova Y.A., Lyutov O.V., Kutlubaev M.A., Bakhtiyarova K.Z.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://nnp.ima-press.net/nnp/article/view/2318">https://nnp.ima-press.net/nnp/article/view/2318</self-uri><abstract><p>In recent decades, the prevalence of demyelinating diseases in paediatric patients has increased rapidly. In this context, there is an increasing need for the study of this pathology in children to enable timely diagnosis and early prescription of highly effective pathogenetic treatment. Neuromyelitis optica spectrum disorders (NMOSD) are a group of severe demyelinating disorders that are united by a single pathogenetic mechanism and primarily affection of the optic nerves and spinal cord. The review presents the main clinical and epidemiological features of NMOSD in the paediatric population. The issues of pathogenesis, which is based on the formation of antibodies against aquaporin-4, and possible therapeutic targets are discussed in detail. The diagnostic criteria and the underlying clinical manifestations as well as their characteristics in childhood are analysed. We present a differential diagnostic framework of the most common diseases, which have to be distinguished from NMOSD in children. Particular attention is paid to the pathogenetic treatment of exacerbations and targeted therapy to prevent exacerbations, which has relatively recently proven its efficacy and been approved for use in paediatric patients.</p></abstract><trans-abstract xml:lang="ru"><p>В последние десятилетия наблюдается быстрый рост распространенности демиелинизирующих заболеваний среди педиатрических пациентов. В связи с этим возрастает необходимость изучения данной патологии у детей для своевременного установления диагноза и раннего назначения высокоэффективного патогенетического лечения. Заболевания спектра оптиконевромиелита (ЗСОНМ) представляют собой группу тяжелых демиелинизирующих заболеваний, объединенных единым патогенетическим механизмом и поражающих в первую очередь зрительные нервы и спинной мозг. В обзоре представлены основные клинико-эпидемиологические характеристики ЗСОНМ в педиатрической популяции. Подробно освещены вопросы патогенеза, в основе которого лежит выработка антител к аквапорину-4, и потенциальных терапевтических мишеней. Разбираются диагностические критерии и лежащие в их основе клинические проявления, а также их особенности в детском возрасте. Представлен дифференциально-диагностический ряд наиболее часто встречающихся состояний, с которыми в первую очередь необходимо дифференцировать ЗСОНМ у детей. Особое внимание уделено патогенетическому лечению обострений и таргетной терапии для предупреждения обострений, которая относительно недавно продемонстрировала эффективность и была одобрена к применению у пациентов детского возраста.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>оптиконевромиелит</kwd><kwd>заболевания спектра оптиконевромиелита</kwd><kwd>аквапорин-4</kwd><kwd>дети</kwd><kwd>дифференциальная диагностика</kwd><kwd>лечение</kwd></kwd-group><kwd-group xml:lang="en"><kwd>neuromyelitis optica</kwd><kwd>neuromyelitis optica spectrum diseases</kwd><kwd>aquaporin-4</kwd><kwd>paediatric patients</kwd><kwd>differential diagnosis</kwd><kwd>treatment</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование не имело спонсорской поддержки</funding-statement><funding-statement xml:lang="en">The investigation has not been sponsored</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Jarius S, Aktas O, Ayzenberg I, et al; Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. J Neurol. 2023 Jul;270(7):3341-68. doi: 10.1007/s00415-023-11634-0. Epub 2023 Apr 6.</mixed-citation><mixed-citation xml:lang="en">Jarius S, Aktas O, Ayzenberg I, et al; Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. J Neurol. 2023 Jul;270(7):3341-68. doi: 10.1007/s00415-023-11634-0. Epub 2023 Apr 6.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Tenembaum S, Yeh EA; Guthy-Jackson Foundation International Clinical Consortium (GJCF-ICC). Pediatric NMOSD: A Review and Position Statement on Approach to WorkUp and Diagnosis. Front Pediatr. 2020 Jun 25;8:339. doi: 10.3389/fped.2020.00339. Erratum in: Front Pediatr. 2021 Feb 15;8:642203. doi: 10.3389/fped.2020.642203</mixed-citation><mixed-citation xml:lang="en">Tenembaum S, Yeh EA; Guthy-Jackson Foundation International Clinical Consortium (GJCF-ICC). Pediatric NMOSD: A Review and Position Statement on Approach to WorkUp and Diagnosis. Front Pediatr. 2020 Jun 25;8:339. doi: 10.3389/fped.2020.00339. Erratum in: Front Pediatr. 2021 Feb 15;8:642203. doi: 10.3389/fped.2020.642203</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Хайбуллин ТН, Кириллова ЕВ, Бикбаев РМ и др. Клинико-эпидемиологические характеристики рассеянного склероза и оптиконейромиелита в Центральной Азии. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2019;119(2-2):12-7. doi: 10.17116/jnevro20191192212</mixed-citation><mixed-citation xml:lang="en">Khaybullin TN, Kirillova EV, Bikbaev RM, et al. Clinical-epidemiological characteristics of multiple sclerosis and neuroopticomyelitis in the Central Asia. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(2-2):12-7. doi: 10.17116/jnevro20191192212 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Papp V, Magyari M, Aktas O, et al. Worldwide Incidence and Prevalence of Neuromyelitis Optica: A Systematic Review. Neurology. 2021 Jan 12;96(2):59-77. doi: 10.1212/WNL.0000000000011153. Epub 2020 Dec 11.</mixed-citation><mixed-citation xml:lang="en">Papp V, Magyari M, Aktas O, et al. Worldwide Incidence and Prevalence of Neuromyelitis Optica: A Systematic Review. Neurology. 2021 Jan 12;96(2):59-77. doi: 10.1212/WNL.0000000000011153. Epub 2020 Dec 11.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Hor JY, Asgari N, Nakashima I, et al. Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Front Neurol. 2020 Jun 26;11:501. doi: 10.3389/fneur.2020.00501</mixed-citation><mixed-citation xml:lang="en">Hor JY, Asgari N, Nakashima I, et al. Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Front Neurol. 2020 Jun 26;11:501. doi: 10.3389/fneur.2020.00501</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Chitnis T, Ness J, Krupp L, et al. Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report. Neurology. 2016 Jan 19;86(3):245-52. doi: 10.1212/WNL.0000000000002283. Epub 2015 Dec 18.</mixed-citation><mixed-citation xml:lang="en">Chitnis T, Ness J, Krupp L, et al. Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report. Neurology. 2016 Jan 19;86(3):245-52. doi: 10.1212/WNL.0000000000002283. Epub 2015 Dec 18.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Fragoso YD, Ferreira ML, Oliveira EM, et al. Neuromyelitis optica with onset in childhood and adolescence. Pediatr Neurol. 2014 Jan;50(1):66-8. doi: 10.1016/j.pediatrneurol.2013.07.003. Epub 2013 Oct 13.</mixed-citation><mixed-citation xml:lang="en">Fragoso YD, Ferreira ML, Oliveira EM, et al. Neuromyelitis optica with onset in childhood and adolescence. Pediatr Neurol. 2014 Jan;50(1):66-8. doi: 10.1016/j.pediatrneurol.2013.07.003. Epub 2013 Oct 13.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Стародубов ВИ, Зеленова ОВ, Абрамов СИ и др. Первое обсервационное эпидемиологическое исследование по определению заболеваемости и распространенности заболеваний спектра оптиконевромиелита (оптиконевромиелит, болезнь Девика) на территории Российской Федерации. Современные проблемы здравоохранения и медицинской статистики. 2021;(1):130-41. doi: 10.24411/2312-2935-2021-00007</mixed-citation><mixed-citation xml:lang="en">Starodubov VI, Zelenova OV, Abramov SI, et al. The first observational epidemiological study to determine the incidence and prevalence of diseases range of neuromyelitis optica (Devic`s disease) on the territory of the Russian Federation. Sovremennyye problemy zdravookhraneniya i meditsinskoy statistiki = Current Problems of Health Care and Medical Statistics. 2021;(1):130-41. https://doi.org/10.24411/2312-2935-2021-00007 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Луцик ВН, Котов АС, Борисова МН и др. Оптикомиелит Девика у ребенка. Неврологический журнал. 2017;22 (4):205-10. doi: 10.18821/1560-9545-2017-22-4-205-210</mixed-citation><mixed-citation xml:lang="en">Lutsik VN, Kotov AS, Borisova MN, et al. Devic’s Neuromyelitis Optica In A Child. Nevrologicheskiy zhurnal = Neurological Journal. 2017;22(4):205-10. doi: 10.18821/1560-9545-2017-22-4-205-210 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Котов АС, Токарева ЮВ, Луцик ВН и др. Расстройство изспектра оптиконевромиелита в детском возрасте (клинический случай). Русский журнал детской неврологии. 2017;(4):56-62. doi: 10.17650/2073-8803-2017-12-4-56-62</mixed-citation><mixed-citation xml:lang="en">Kotov AS, Tokareva YuV, Lutsik VN, et al. Neuromyelitis optica spectrum disorder in childhood (a case report). Russkiy zhurnal detskoy nevrologii = Russian Journal of Child Neurology. 2017;(4):56-62. doi: 10.17650/2073-8803-2017-12-4-56-62 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Токарева ЮВ, Котов АС, Пантелеева МВ и др. Расстройства из спектра оптиконевромиелита у пациентов детского возраста. Неврология, нейропсихиатрия, психосоматика. 2018;10(1):60-4. doi: 10.14412/2074-2711-2018-1-60-64</mixed-citation><mixed-citation xml:lang="en">Tokareva YuV, Kotov AS, Panteleeva MV, et al. Neuromyelitis optica spectrum disorders in pediatric patients. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(1):60-4. doi: 10.14412/2074-2711-2018-1-60-64 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Abe Y, Yasui M. Aquaporin-4 in Neuromyelitis Optica Spectrum Disorders: A Target of Autoimmunity in the Central Nervous System. Biomolecules. 2022 Apr 17;12(4):591. doi: 10.3390/biom12040591</mixed-citation><mixed-citation xml:lang="en">Abe Y, Yasui M. Aquaporin-4 in Neuromyelitis Optica Spectrum Disorders: A Target of Autoimmunity in the Central Nervous System. Biomolecules. 2022 Apr 17;12(4):591. doi: 10.3390/biom12040591</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Зайцева ПА, Бойко АН. Заболевания спектра оптиконевромиелита: от патогенеза к таргетной терапии. Неврология, нейропсихиатрия, психосоматика. 2023;15(Прил. 1):49-57. doi: 10.14412/2074-2711-2023-1S-49-57</mixed-citation><mixed-citation xml:lang="en">Zaitseva PA, Boyko AN. Neuromyelitis optic spectrum disorders (NMOSD): from pathogenesis to targeted therapy. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(S1):49-57. doi: 10.14412/2074-2711-2023-1S-49-57 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Trebst C, Jarius S, Berthele A, et al; Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014 Jan;261(1):1-16. doi: 10.1007/s00415-013-7169-7. Epub 2013 Nov 23.</mixed-citation><mixed-citation xml:lang="en">Trebst C, Jarius S, Berthele A, et al; Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014 Jan;261(1):1-16. doi: 10.1007/s00415-013-7169-7. Epub 2013 Nov 23.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Cazzaniga J, Jara Silva CE, Quinonez J, et al. Neuromyelitis Optica Spectrum Disorder. Cureus. 2023 Nov 2;15(11):e48168. doi: 10.7759/cureus.48168</mixed-citation><mixed-citation xml:lang="en">Cazzaniga J, Jara Silva CE, Quinonez J, et al. Neuromyelitis Optica Spectrum Disorder. Cureus. 2023 Nov 2;15(11):e48168. doi: 10.7759/cureus.48168</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Grebenciucova E, VanHaerents S. Interleukin 6: at the interface of human health and disease. Front Immunol. 2023 Sep 28;14:1255533. doi: 10.3389/fimmu.2023.1255533</mixed-citation><mixed-citation xml:lang="en">Grebenciucova E, VanHaerents S. Interleukin 6: at the interface of human health and disease. Front Immunol. 2023 Sep 28;14:1255533. doi: 10.3389/fimmu.2023.1255533</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Fujihara K, Bennett JL, de Seze J, et al. Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurol Neuroimmunol Neuroinflamm. 2020 Aug 20;7(5):e841. doi: 10.1212/NXI.0000000000000841</mixed-citation><mixed-citation xml:lang="en">Fujihara K, Bennett JL, de Seze J, et al. Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurol Neuroimmunol Neuroinflamm. 2020 Aug 20;7(5):e841. doi: 10.1212/NXI.0000000000000841</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Симанив ТО, Бахтиярова КЗ, Белова АН и др. Заболевания спектра оптиконевромиелита (ЗСОНМ) – диагностические критерии и подходы к терапии. Неврология, нейропсихиатрия, психосоматика. 2023;15(Прил. 1):71-5. doi: 10.14412/2074-2711-2023-1S-71-75</mixed-citation><mixed-citation xml:lang="en">Simaniv TO, Bakhtiyarova KZ, Belova AN, et al. Diagnostic criteria and treatment of neuromyelitis optica spectrum disorders (NMOSD). Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(S1):71-5. doi: 10.14412/2074-2711-2023-1S-71-75 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Yan Y, Li Y, Fu Y, et al. Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD. Sci China Life Sci. 2016 Dec;59(12):1270-81. doi: 10.1007/s11427-015-4997-y. Epub 2016 Feb 26.</mixed-citation><mixed-citation xml:lang="en">Yan Y, Li Y, Fu Y, et al. Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD. Sci China Life Sci. 2016 Dec;59(12):1270-81. doi: 10.1007/s11427-015-4997-y. Epub 2016 Feb 26.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Bruijstens AL, Lechner C, Flet-Berliac L, et al. E.U. paediatric MOG consortium consensus: Part 1 – Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. 2020 Nov;29:2-13. doi: 10.1016/j.ejpn.2020.10.006. Epub 2020 Nov 4.</mixed-citation><mixed-citation xml:lang="en">Bruijstens AL, Lechner C, Flet-Berliac L, et al. E.U. paediatric MOG consortium consensus: Part 1 – Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. 2020 Nov;29:2-13. doi: 10.1016/j.ejpn.2020.10.006. Epub 2020 Nov 4.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Wingerchuk DM, Banwell B, Bennett JL, et al; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 Jul 14;85(2):177-89. doi: 10.1212/WNL.0000000000001729. Epub 2015 Jun 19.</mixed-citation><mixed-citation xml:lang="en">Wingerchuk DM, Banwell B, Bennett JL, et al; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 Jul 14;85(2):177-89. doi: 10.1212/WNL.0000000000001729. Epub 2015 Jun 19.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Белова АН, Бойко АН, Белова ЕМ. Диагностические критерии оптикомиелит- ассоциированных расстройств. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2016;116(2-2):32-40. doi: 10.17116/jnevro20161162232-40</mixed-citation><mixed-citation xml:lang="en">Belova AN, Boiko AN, Belova EM. Diagnostic criteria for neuromyelitisoptica spectrum disor- ders. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(2-2):32-40. doi: 10.17116/jnevro20161162232-40 (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Baghbanian SM, Asgari N, Sahraian MA, Moghadasi AN. A comparison of pediatric and adult neuromyelitis optica spectrum disorders: A review of clinical manifestation, diagnosis, and treatment. J Neurol Sci. 2018 May 15;388:222-31. doi: 10.1016/j.jns.2018.02.028. Epub 2018 Feb 19.</mixed-citation><mixed-citation xml:lang="en">Baghbanian SM, Asgari N, Sahraian MA, Moghadasi AN. A comparison of pediatric and adult neuromyelitis optica spectrum disorders: A review of clinical manifestation, diagnosis, and treatment. J Neurol Sci. 2018 May 15;388:222-31. doi: 10.1016/j.jns.2018.02.028. Epub 2018 Feb 19.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Paolilo RB, Hacohen Y, Yazbeck E, et al. Treatment and outcome of aquaporin-4 antibody-positive NMOSD: A multinational pediatric study. Neurol Neuroimmunol Neuroinflamm. 2020 Jul 30;7(5):e837. doi: 10.1212/NXI.0000000000000837</mixed-citation><mixed-citation xml:lang="en">Paolilo RB, Hacohen Y, Yazbeck E, et al. Treatment and outcome of aquaporin-4 antibody-positive NMOSD: A multinational pediatric study. Neurol Neuroimmunol Neuroinflamm. 2020 Jul 30;7(5):e837. doi: 10.1212/NXI.0000000000000837</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Camera V, Messina S, Elhadd KT, et al. Early predictors of disability of paediatric-onset AQP4-IgG-seropositive neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry. 2022 Jan;93(1):101-11. doi: 10.1136/jnnp-2021-327206. Epub 2021 Sep 28.</mixed-citation><mixed-citation xml:lang="en">Camera V, Messina S, Elhadd KT, et al. Early predictors of disability of paediatric-onset AQP4-IgG-seropositive neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry. 2022 Jan;93(1):101-11. doi: 10.1136/jnnp-2021-327206. Epub 2021 Sep 28.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Hacohen Y, Messina S, Gan HW, et al. Endocrinopathies in paediatric-onset neuromyelitis optica spectrum disorder with aquaporin 4 (AQP4) antibody. Mult Scler. 2018 Apr;24(5):679-84. doi: 10.1177/1352458517726593. Epub 2017 Aug 14.</mixed-citation><mixed-citation xml:lang="en">Hacohen Y, Messina S, Gan HW, et al. Endocrinopathies in paediatric-onset neuromyelitis optica spectrum disorder with aquaporin 4 (AQP4) antibody. Mult Scler. 2018 Apr;24(5):679-84. doi: 10.1177/1352458517726593. Epub 2017 Aug 14.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Kim HJ, Paul F, Lana-Peixoto MA, et al; Guthy-Jackson Charitable Foundation NMO International Clinical Consortium &amp; Biorepository. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology. 2015 Mar 17;84(11):1165-73. doi: 10.1212/WNL.0000000000001367. Epub 2015 Feb 18.</mixed-citation><mixed-citation xml:lang="en">Kim HJ, Paul F, Lana-Peixoto MA, et al; Guthy-Jackson Charitable Foundation NMO International Clinical Consortium &amp; Biorepository. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology. 2015 Mar 17;84(11):1165-73. doi: 10.1212/WNL.0000000000001367. Epub 2015 Feb 18.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Bourre B, Zephir H, Ongagna JC, et al. Long-term follow-up of acute partial transverse</mixed-citation><mixed-citation xml:lang="en">Bourre B, Zephir H, Ongagna JC, et al. Long-term follow-up of acute partial transverse</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Huh SY, Min JH, Kim W, et al. The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders. Mult Scler. 2014 May;20(6):695-704. doi: 10.1177/1352458513506953. Epub 2013 Sep 26.</mixed-citation><mixed-citation xml:lang="en">Huh SY, Min JH, Kim W, et al. The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders. Mult Scler. 2014 May;20(6):695-704. doi: 10.1177/1352458513506953. Epub 2013 Sep 26.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Baumann M, Sahin K, Lechner C, et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry. 2015 Mar;86(3):265-72. doi: 10.1136/jnnp-2014-308346. Epub 2014 Aug 13.</mixed-citation><mixed-citation xml:lang="en">Baumann M, Sahin K, Lechner C, et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry. 2015 Mar;86(3):265-72. doi: 10.1136/jnnp-2014-308346. Epub 2014 Aug 13.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006 May 23;66(10):1485-9. doi: 10.1212/01.wnl.0000216139.44259.74</mixed-citation><mixed-citation xml:lang="en">Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006 May 23;66(10):1485-9. doi: 10.1212/01.wnl.0000216139.44259.74</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Matthews L, Marasco R, Jenkinson M, et al. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology. 2013 Apr 2;80(14):1330-7. doi: 10.1212/WNL.0b013e3182887957. Epub 2013 Mar 13.</mixed-citation><mixed-citation xml:lang="en">Matthews L, Marasco R, Jenkinson M, et al. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology. 2013 Apr 2;80(14):1330-7. doi: 10.1212/WNL.0b013e3182887957. Epub 2013 Mar 13.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Mader S, Obholzer B, Reindl M. Relevance of Autoantibodies for the Classification and Pathogenesis of Neurological Diseases. Autoimmune Disorders – Current Concepts and Advances from Bedside to Mechanistic Insights. InTech. 2011. doi: 10.5772/20517</mixed-citation><mixed-citation xml:lang="en">Mader S, Obholzer B, Reindl M. Relevance of Autoantibodies for the Classification and Pathogenesis of Neurological Diseases. Autoimmune Disorders – Current Concepts and Advances from Bedside to Mechanistic Insights. InTech. 2011. doi: 10.5772/20517</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Yin HX, Wang YJ, Liu MG, et al. Aquaporin-4 Antibody Dynamics and Relapse Risk in Seropositive Neuromyelitis Optica Spectrum Disorder Treated with Immunosuppressants. Ann Neurol. 2023 Jun;93(6):1069-81. doi: 10.1002/ana.26623. Epub 2023 Mar 13.</mixed-citation><mixed-citation xml:lang="en">Yin HX, Wang YJ, Liu MG, et al. Aquaporin-4 Antibody Dynamics and Relapse Risk in Seropositive Neuromyelitis Optica Spectrum Disorder Treated with Immunosuppressants. Ann Neurol. 2023 Jun;93(6):1069-81. doi: 10.1002/ana.26623. Epub 2023 Mar 13.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Poisson K, Moeller K, Fisher KS. Pediatric Neuromyelitis Optica Spectrum Disorder. Semin Pediatr Neurol. 2023 Jul;46:101051. doi: 10.1016/j.spen.2023.101051. Epub 2023 Apr 30.</mixed-citation><mixed-citation xml:lang="en">Poisson K, Moeller K, Fisher KS. Pediatric Neuromyelitis Optica Spectrum Disorder. Semin Pediatr Neurol. 2023 Jul;46:101051. doi: 10.1016/j.spen.2023.101051. Epub 2023 Apr 30.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Shahmohammadi S, Doosti R, Shahmohammadi A, et al. Autoimmune diseases associated with Neuromyelitis Optica Spectrum Disorders: A literature review. Mult Scler Relat Disord. 2019 Jan;27:350-63. doi: 10.1016/j.msard.2018.11.008. Epub 2018 Nov 16.</mixed-citation><mixed-citation xml:lang="en">Shahmohammadi S, Doosti R, Shahmohammadi A, et al. Autoimmune diseases associated with Neuromyelitis Optica Spectrum Disorders: A literature review. Mult Scler Relat Disord. 2019 Jan;27:350-63. doi: 10.1016/j.msard.2018.11.008. Epub 2018 Nov 16.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Mealy MA, Kozachik SL, Levy M. Review of Treatment for Central Spinal Neuropathic Pain and Its Effect on Quality of Life: Implications for Neuromyelitis Optica Spectrum Disorder. Pain Manag Nurs. 2019 Dec;20(6):580-91. doi: 10.1016/j.pmn.2019.03.003. Epub 2019 May 15.</mixed-citation><mixed-citation xml:lang="en">Mealy MA, Kozachik SL, Levy M. Review of Treatment for Central Spinal Neuropathic Pain and Its Effect on Quality of Life: Implications for Neuromyelitis Optica Spectrum Disorder. Pain Manag Nurs. 2019 Dec;20(6):580-91. doi: 10.1016/j.pmn.2019.03.003. Epub 2019 May 15.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Ferilli MAN, Paparella R, Morandini I, et al. Pediatric Neuromyelitis Optica Spectrum Disorder: Case Series and Literature Review. Life (Basel). 2021 Dec 23;12(1):19. doi: 10.3390/life12010019 A systematic review and meta-analysis. J Neuroimmunol. 2020 Nov 20;350:577449. doi: 10.1016/j.jneuroim.2020.577449. Epub ahead of print.</mixed-citation><mixed-citation xml:lang="en">Ferilli MAN, Paparella R, Morandini I, et al. Pediatric Neuromyelitis Optica Spectrum Disorder: Case Series and Literature Review. Life (Basel). 2021 Dec 23;12(1):19. doi: 10.3390/life12010019 A systematic review and meta-analysis. J Neuroimmunol. 2020 Nov 20;350:577449. doi: 10.1016/j.jneuroim.2020.577449. Epub ahead of print.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Li Z, Wan L, Liu X, et al. Safety and efficacy of plasma exchange treatment in children with AQP4-IgG positive neuromyelitis optica spectrum disorder. Front Immunol. 2023 Jan 5;13:1113406. doi: 10.3389/fimmu.2022.1113406</mixed-citation><mixed-citation xml:lang="en">Li Z, Wan L, Liu X, et al. Safety and efficacy of plasma exchange treatment in children with AQP4-IgG positive neuromyelitis optica spectrum disorder. Front Immunol. 2023 Jan 5;13:1113406. doi: 10.3389/fimmu.2022.1113406</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou Y, Zhong X, Shu Y, et al. Clinical course, treatment responses and outcomes in Chinese paediatric neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2019 Feb;28:213-20. doi: 10.1016/j.msard.2018.12.038. Epub 2019 Jan 3.</mixed-citation><mixed-citation xml:lang="en">Zhou Y, Zhong X, Shu Y, et al. Clinical course, treatment responses and outcomes in Chinese paediatric neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2019 Feb;28:213-20. doi: 10.1016/j.msard.2018.12.038. Epub 2019 Jan 3.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Paolilo RB, da Paz JA, Apostolos-Pereira SL, et al. Reduced quality of life in a pediatric-onset Neuromyelitis optica spectrum disorders cohort. Mult Scler Relat Disord. 2021 Nov;56:103252. doi: 10.1016/j.msard.2021.103252. Epub 2021 Sep 10.</mixed-citation><mixed-citation xml:lang="en">Paolilo RB, da Paz JA, Apostolos-Pereira SL, et al. Reduced quality of life in a pediatric-onset Neuromyelitis optica spectrum disorders cohort. Mult Scler Relat Disord. 2021 Nov;56:103252. doi: 10.1016/j.msard.2021.103252. Epub 2021 Sep 10.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Kim SH, Kim W, Li XF, et al. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Mult Scler. 2012 Oct;18(10):1480-3. doi: 10.1177/1352458512439439. Epub 2012 Feb 21.</mixed-citation><mixed-citation xml:lang="en">Kim SH, Kim W, Li XF, et al. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Mult Scler. 2012 Oct;18(10):1480-3. doi: 10.1177/1352458512439439. Epub 2012 Feb 21.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Ayzenberg I, Schöllhammer J, Hoepner R, et al; Neuromyelitis Optica Study Group. Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retro- spective study. J Neurol. 2016 Mar;263(3):575-82. doi: 10.1007/s00415-015-7991-1. Epub 2016 Jan 25.</mixed-citation><mixed-citation xml:lang="en">Ayzenberg I, Schöllhammer J, Hoepner R, et al; Neuromyelitis Optica Study Group. Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retro- spective study. J Neurol. 2016 Mar;263(3):575-82. doi: 10.1007/s00415-015-7991-1. Epub 2016 Jan 25.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler. 2012 Jan;18(1):113-5. doi: 10.1177/1352458511431973. Epub 2011 Dec 6.</mixed-citation><mixed-citation xml:lang="en">Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler. 2012 Jan;18(1):113-5. doi: 10.1177/1352458511431973. Epub 2011 Dec 6.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Bonnan M, Berthelot E, Cabre P. Multiple sclerosis-like NMOSD patients suffer severe worsening of status after fingolimod initiation. Mult Scler Relat Disord. 2021 Jul;52:102975. doi: 10.1016/j.msard.2021.102975. Epub 2021 Apr 24.</mixed-citation><mixed-citation xml:lang="en">Bonnan M, Berthelot E, Cabre P. Multiple sclerosis-like NMOSD patients suffer severe worsening of status after fingolimod initiation. Mult Scler Relat Disord. 2021 Jul;52:102975. doi: 10.1016/j.msard.2021.102975. Epub 2021 Apr 24.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Gahlen A, Trampe AK, Haupeltshofer S, et al. Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS. Neurol Neuroimmunol Neuroinflamm. 2017 Jun 16;4(4):e363. doi: 10.1212/NXI.0000000000000363</mixed-citation><mixed-citation xml:lang="en">Gahlen A, Trampe AK, Haupeltshofer S, et al. Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS. Neurol Neuroimmunol Neuroinflamm. 2017 Jun 16;4(4):e363. doi: 10.1212/NXI.0000000000000363</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Azzopardi L, Cox AL, McCarthy CL, et al. Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series. J Neurol. 2016 Jan;263(1):25-9. doi: 10.1007/s00415-015-7925-y</mixed-citation><mixed-citation xml:lang="en">Azzopardi L, Cox AL, McCarthy CL, et al. Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series. J Neurol. 2016 Jan;263(1):25-9. doi: 10.1007/s00415-015-7925-y</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Yamout BI, Beaini S, Zeineddine MM, Akkawi N. Catastrophic relapses following initiation of dimethyl fumarate in two patients with neuromyelitis optica spectrum disorder. myelitis. Arch Neurol. 2012 Mar;69(3):357-62. doi: 10.1001/archneurol.2011.949. Erratum in: Arch Neurol. 2012 Jun;69(6):789.</mixed-citation><mixed-citation xml:lang="en">Yamout BI, Beaini S, Zeineddine MM, Akkawi N. Catastrophic relapses following initiation of dimethyl fumarate in two patients with neuromyelitis optica spectrum disorder. myelitis. Arch Neurol. 2012 Mar;69(3):357-62. doi: 10.1001/archneurol.2011.949. Erratum in: Arch Neurol. 2012 Jun;69(6):789.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Yu HH, Qin C, Zhang SQ, et al. Efficacy of plasma exchange in acute attacks of neuromyelitis optica spectrum disorders: Mult Scler. 2017 Aug;23(9):1297-300. doi: 10.1177/1352458517694086. Epub 2017 Apr 10.</mixed-citation><mixed-citation xml:lang="en">Yu HH, Qin C, Zhang SQ, et al. Efficacy of plasma exchange in acute attacks of neuromyelitis optica spectrum disorders: Mult Scler. 2017 Aug;23(9):1297-300. doi: 10.1177/1352458517694086. Epub 2017 Apr 10.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Прахова ЛН, Краснов ВС, Касаткин ДС и др. Локальный опыт применения препарата сатрализумаб, подавляющего путь IL-6, для терапии заболеваний спектра оптиконейромиелита. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2022;122(7-2):68-72. doi: 10.17116/jnevro202212207268</mixed-citation><mixed-citation xml:lang="en">Prakhova LN, Krasnov VS, Kasatkin DS, et al. Local experience of IL-6 pathway inhibition with satralizumab for patients with neuromyelitis optica spectrum disorder. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. Spetsvypuski = S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(7-2):68-72. doi: 10.17116/jnevro202212207268 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Heo YA. Satralizumab: First Approval. Drugs. 2020 Sep;80(14):1477-82. doi: 10.1007/s40265-020-01380-2. Erratum in: Drugs. 2020 Sep;80(14):1483. doi: 10.1007/s40265-020-01391-z</mixed-citation><mixed-citation xml:lang="en">Heo YA. Satralizumab: First Approval. Drugs. 2020 Sep;80(14):1477-82. doi: 10.1007/s40265-020-01380-2. Erratum in: Drugs. 2020 Sep;80(14):1483. doi: 10.1007/s40265-020-01391-z</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Yamamura T, Kleiter I, Fujihara K, et al. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019 Nov 28;381(22):2114-24. doi: 10.1056/NEJMoa1901747</mixed-citation><mixed-citation xml:lang="en">Yamamura T, Kleiter I, Fujihara K, et al. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019 Nov 28;381(22):2114-24. doi: 10.1056/NEJMoa1901747</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Li X, Wu W, Zeng Y, et al. Satralizumab as an add-on treatment in refractory pediatric AQP4-antibody-positive neuromyelitis optica spectrum disorder: a case report. Front Immunol. 2023 Oct 17;14:1257955. doi: 10.3389/fimmu.2023.1257955</mixed-citation><mixed-citation xml:lang="en">Li X, Wu W, Zeng Y, et al. Satralizumab as an add-on treatment in refractory pediatric AQP4-antibody-positive neuromyelitis optica spectrum disorder: a case report. Front Immunol. 2023 Oct 17;14:1257955. doi: 10.3389/fimmu.2023.1257955</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019 Aug 15;381(7):614-25. doi: 10.1056/NEJMoa1900866. Epub 2019 May 3.</mixed-citation><mixed-citation xml:lang="en">Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019 Aug 15;381(7):614-25. doi: 10.1056/NEJMoa1900866. Epub 2019 May 3.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Pittock SJ, Barnett M, Bennett JL, et al. Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. Ann Neurol. 2023 Jun;93(6):1053-68. doi: 10.1002/ana.26626. Epub 2023 Apr 5.</mixed-citation><mixed-citation xml:lang="en">Pittock SJ, Barnett M, Bennett JL, et al. Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. Ann Neurol. 2023 Jun;93(6):1053-68. doi: 10.1002/ana.26626. Epub 2023 Apr 5.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Резолюция Междисциплинарного совета экспертов по профилактике тяжелых инфекций у пациентов с генетическими нарушениями регуляции системы комплемента, получающих терапию экулизумабом. Эпидемиология и вакцинопрофилактика. 2017;16(1):51-4.</mixed-citation><mixed-citation xml:lang="en">Resolution of the interdisciplinary council experts for prevention of severe infections in patients with genetic disorders of regulation of the complement system, receiving therapy with eculizumab. Epidemiologiya i vaktsinoprofilaktika = Epidemiology and Vaccinal Prevention. 2017;16(1):51-4 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014 Jul 8;83(2):142-50. doi: 10.1212/WNL.0000000000000570. Epub 2014 Jun 11.</mixed-citation><mixed-citation xml:lang="en">Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014 Jul 8;83(2):142-50. doi: 10.1212/WNL.0000000000000570. Epub 2014 Jun 11.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Nosadini M, Alper G, Riney CJ, et al. Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2016 Jan 21;3(1):e188. doi: 10.1212/NXI.0000000000000188</mixed-citation><mixed-citation xml:lang="en">Nosadini M, Alper G, Riney CJ, et al. Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2016 Jan 21;3(1):e188. doi: 10.1212/NXI.0000000000000188</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Deya-Martinez A, Gordon Y, Molina-Anguita C, et al. Single-cycle rituximab-induced immunologic changes in children: Enhanced in neuroimmunologic disease? Neurol Neuroimmunol Neuroinflamm. 2020 May 6;7(4):e724. doi: 10.1212/NXI.0000000000000724</mixed-citation><mixed-citation xml:lang="en">Deya-Martinez A, Gordon Y, Molina-Anguita C, et al. Single-cycle rituximab-induced immunologic changes in children: Enhanced in neuroimmunologic disease? Neurol Neuroimmunol Neuroinflamm. 2020 May 6;7(4):e724. doi: 10.1212/NXI.0000000000000724</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Espiritu AI, Pasco PMD. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis. Mult Scler Relat Disord. 2019 Aug;33:22-32. doi: 10.1016/j.msard.2019.05.011. Epub 2019 May 22.</mixed-citation><mixed-citation xml:lang="en">Espiritu AI, Pasco PMD. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis. Mult Scler Relat Disord. 2019 Aug;33:22-32. doi: 10.1016/j.msard.2019.05.011. Epub 2019 May 22.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
